Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel disease.
Gastroenterology and Hepatology Unit, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.
Beatriz
B
Castro
Gastroenterology and Hepatology Unit, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.
Montserrat
M
Rivero
Gastroenterology and Hepatology Unit, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.
Javier
J
Crespo
Department of Internal Medicine, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.
J Antonio
JA
Riancho
Department of Internal Medicine, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain. Electronic address: mirvdc@humv.es.
Carmen
C
Valero
D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D002112:Calcifediol / Q000097:blood; D005260:Female; D006785:Hospitals, University; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000453:epidemiology; D013030:Spain; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D002112:Calcifediol